Cocrystal Pharma Files 8-K
Ticker: COCP · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, Regulation FD, financial-statements
TL;DR
Cocrystal Pharma filed an 8-K on 12/18/25, standard reporting.
AI Summary
Cocrystal Pharma, Inc. filed an 8-K on December 18, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, incorporated in Delaware, has its principal executive offices in Bothell, WA.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and exhibits, which provides transparency to investors about the company's status.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain any material non-public information or significant events.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Bothell, WA (location) — Principal executive offices
- December 18, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report under Regulation FD and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 18, 2025.
In which state is Cocrystal Pharma, Inc. incorporated?
Cocrystal Pharma, Inc. is incorporated in Delaware.
What is the address of Cocrystal Pharma, Inc.'s principal executive offices?
The address of Cocrystal Pharma, Inc.'s principal executive offices is 19805 N. Creek Parkway, Bothell, WA 98011.
What is the IRS Employer Identification Number for Cocrystal Pharma, Inc.?
The IRS Employer Identification Number for Cocrystal Pharma, Inc. is 35-2528215.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-12-18 09:00:25
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 18KB
- 0001493152-25-028296.txt ( ) — 248KB
- cocp-20251218.xsd (EX-101.SCH) — 3KB
- cocp-20251218_lab.xml (EX-101.LAB) — 33KB
- cocp-20251218_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cocrystal Pharma, Inc. Date: December 18, 2025 By: /s/ James Martin Name: James Martin Title: Co-Chief Executive Officer and Chief Financial Officer